160 related articles for article (PubMed ID: 12845650)
1. Anti-CD30-IL-12 antibody-cytokine fusion protein that induces IFN-gamma secretion of T cells and NK cell-mediated lysis of Hodgkin's lymphoma-derived tumor cells.
Heuser C; Diehl V; Abken H; Hombach A
Int J Cancer; 2003 Sep; 106(4):545-552. PubMed ID: 12845650
[TBL] [Abstract][Full Text] [Related]
2. Anti-CD30-scFv-Fc-IL-2 antibody-cytokine fusion protein that induces resting NK cells to highly efficient cytolysis of Hodgkin's lymphoma derived tumour cells.
Heuser C; Guhlke S; Matthies A; Bender H; Barth S; Diehl V; Abken H; Hombach A
Int J Cancer; 2004 Jun; 110(3):386-94. PubMed ID: 15095304
[TBL] [Abstract][Full Text] [Related]
3. Characterization of a chimeric T-cell receptor with specificity for the Hodgkin's lymphoma-associated CD30 antigen.
Hombach A; Heuser C; Sircar R; Tillmann T; Diehl V; Pohl C; Abken H
J Immunother; 1999 Nov; 22(6):473-80. PubMed ID: 10570745
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous targeting of IL2 and IL12 to Hodgkin's lymphoma cells enhances activation of resting NK cells and tumor cell lysis.
Hombach A; Heuser C; Abken H
Int J Cancer; 2005 Jun; 115(2):241-7. PubMed ID: 15688386
[TBL] [Abstract][Full Text] [Related]
5. An IL12-IL2-antibody fusion protein targeting Hodgkin's lymphoma cells potentiates activation of NK and T cells for an anti-tumor attack.
Jahn T; Zuther M; Friedrichs B; Heuser C; Guhlke S; Abken H; Hombach AA
PLoS One; 2012; 7(9):e44482. PubMed ID: 23028547
[TBL] [Abstract][Full Text] [Related]
6. A CD16/CD30 bispecific monoclonal antibody induces lysis of Hodgkin's cells by unstimulated natural killer cells in vitro and in vivo.
Hombach A; Jung W; Pohl C; Renner C; Sahin U; Schmits R; Wolf J; Kapp U; Diehl V; Pfreundschuh M
Int J Cancer; 1993 Nov; 55(5):830-6. PubMed ID: 8244580
[TBL] [Abstract][Full Text] [Related]
7. Activation of Hodgkin cells via the CD30 receptor induces autocrine secretion of interleukin-6 engaging the NF-kappabeta transcription factor.
Gruss HJ; Ulrich D; Dower SK; Herrmann F; Brach MA
Blood; 1996 Mar; 87(6):2443-9. PubMed ID: 8630409
[TBL] [Abstract][Full Text] [Related]
8. CD30 is involved in inhibition of T-cell proliferation by Hodgkin's Reed-Sternberg cells.
Su CC; Chiu HH; Chang CC; Chen JC; Hsu SM
Cancer Res; 2004 Mar; 64(6):2148-52. PubMed ID: 15026356
[TBL] [Abstract][Full Text] [Related]
9. An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4(scFv)-ETA') is a potent immunotoxin against a Hodgkin-derived cell line.
Klimka A; Barth S; Matthey B; Roovers RC; Lemke H; Hansen H; Arends JW; Diehl V; Hoogenboom HR; Engert A
Br J Cancer; 1999 Jun; 80(8):1214-22. PubMed ID: 10376974
[TBL] [Abstract][Full Text] [Related]
10. An anti-CD30 chimeric receptor that mediates CD3-zeta-independent T-cell activation against Hodgkin's lymphoma cells in the presence of soluble CD30.
Hombach A; Heuser C; Sircar R; Tillmann T; Diehl V; Pohl C; Abken H
Cancer Res; 1998 Mar; 58(6):1116-9. PubMed ID: 9515791
[TBL] [Abstract][Full Text] [Related]
11. CD30-antigen-specific targeting and activation of T cells via murine bispecific monoclonal antibodies against CD3 and CD28: potential use for the treatment of Hodgkin's lymphoma.
Pohl C; Denfeld R; Renner C; Jung W; Bohlen H; Sahin U; Hombach A; van Lier R; Schwonzen M; Diehl V
Int J Cancer; 1993 Jul; 54(5):820-7. PubMed ID: 7686889
[TBL] [Abstract][Full Text] [Related]
12. Immune recruitment by bispecific antibodies for the treatment of Hodgkin disease.
da Costa L; Renner C; Hartmann F; Pfreundschuh M
Cancer Chemother Pharmacol; 2000; 46 Suppl():S33-6. PubMed ID: 10950145
[TBL] [Abstract][Full Text] [Related]
13. The B7/BB1 antigen is expressed by Reed-Sternberg cells of Hodgkin's disease and contributes to the stimulating capacity of Hodgkin's disease-derived cell lines.
Delabie J; Ceuppens JL; Vandenberghe P; de Boer M; Coorevits L; De Wolf-Peeters C
Blood; 1993 Nov; 82(9):2845-52. PubMed ID: 7693051
[TBL] [Abstract][Full Text] [Related]
14. Development of new ricin A-chain immunotoxins with potent anti-tumor effects against human Hodgkin cells in vitro and disseminated Hodgkin tumors in SCID mice using high-affinity monoclonal antibodies directed against the CD30 antigen.
Schnell R; Linnartz C; Katouzi AA; Schön G; Bohlen H; Horn-Lohrens O; Parwaresch RM; Lange H; Diehl V; Lemke H
Int J Cancer; 1995 Oct; 63(2):238-44. PubMed ID: 7591211
[TBL] [Abstract][Full Text] [Related]
15. A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells.
Reusch U; Burkhardt C; Fucek I; Le Gall F; Le Gall M; Hoffmann K; Knackmuss SH; Kiprijanov S; Little M; Zhukovsky EA
MAbs; 2014; 6(3):728-39. PubMed ID: 24670809
[TBL] [Abstract][Full Text] [Related]
16. Autocrine growth regulation of CD30 ligand in CD30-expressing Reed-Sternberg cells: distinction between Hodgkin's disease and anaplastic large cell lymphoma.
Hsu PL; Hsu SM
Lab Invest; 2000 Jul; 80(7):1111-9. PubMed ID: 10908157
[TBL] [Abstract][Full Text] [Related]
17. CD30 ligand expression in nonmalignant and Hodgkin's disease-involved lymphoid tissues.
Gruss HJ; Pinto A; Gloghini A; Wehnes E; Wright B; Boiani N; Aldinucci D; Gattei V; Zagonel V; Smith CA; Kadin ME; von Schilling C; Goodwin RG; Herrmann F; Carbone A
Am J Pathol; 1996 Aug; 149(2):469-81. PubMed ID: 8701986
[TBL] [Abstract][Full Text] [Related]
18. Expression and function of CD40 on Hodgkin and Reed-Sternberg cells and the possible relevance for Hodgkin's disease.
Gruss HJ; Hirschstein D; Wright B; Ulrich D; Caligiuri MA; Barcos M; Strockbine L; Armitage RJ; Dower SK
Blood; 1994 Oct; 84(7):2305-14. PubMed ID: 7522624
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-12 increases bispecific-antibody-mediated natural killer cell cytotoxicity against human tumors.
Sahin U; Kraft-Bauer S; Ohnesorge S; Pfreundschuh M; Renner C
Cancer Immunol Immunother; 1996 Jan; 42(1):9-14. PubMed ID: 8625370
[TBL] [Abstract][Full Text] [Related]
20. Expression of functional CD40 antigen on Reed-Sternberg cells and Hodgkin's disease cell lines.
Carbone A; Gloghini A; Gattei V; Aldinucci D; Degan M; De Paoli P; Zagonel V; Pinto A
Blood; 1995 Feb; 85(3):780-9. PubMed ID: 7530508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]